Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS

Core Insights - Wall Street analysts expect Danaher (DHR) to report quarterly earnings of $1.62 per share, reflecting a year-over-year decline of 15.6$5.56 billion, down 4.2% from the same quarter last year [1] - The consensus EPS estimate has been revised 0.1% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Revenue Estimates - The consensus estimate for 'Total sales- Diagnostics' is $2.34 billion, indicating a decline of 7.2$1.64 billion, reflecting a decrease of 6% year-over-year [4] - 'Total sales- Biotechnology' is projected at $1.59 billion, suggesting a year-over-year increase of 4$199.97 million, down from $235 million reported in the same quarter last year [5] - 'Operating profit- Biotechnology' is expected to reach$398.00 million, compared to $325 million in the same quarter of the previous year [5] - The estimated 'Operating profit- Diagnostics' stands at$585.46 million, a decrease from $830 million a year ago [6] Stock Performance - Over the past month, Danaher's shares have returned -10.7%, while the Zacks S&P 500 composite has changed by -4.2% [6] - Currently, Danaher carries a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [6]